We are excited to announce positive topline safety and - TopicsExpress



          

We are excited to announce positive topline safety and tolerability results from our Phase 1a clinical trial of SYN-004, our first-in-class drug candidate for the prevention of C. difficile infection. We expect enrollment into our Phase 1b SYN-004 clinical trial to begin before year-end, with topline data available during the first quarter of 2015. We also expect to initiate enrollment in a Phase 2 SYN-004 clinical trial ahead of schedule during the first quarter of 2015. SYN-004 is Synthetic Biologics’ oral drug candidate designed to be the first treatment intended to prevent C. difficile infection. The U.S. Centers for Disease Control (CDC) has identified C. difficile as an “urgent public health threat” and occurs mostly in people who have had recent medical care with IV antibiotics. #Cdiff bit.ly/1sQbCSo
Posted on: Mon, 22 Dec 2014 14:47:31 +0000

Trending Topics



Recently Viewed Topics




© 2015